Jason Coloma is Chief Executive Officer of Maze Therapeutics, Inc. (MAZE). The company reported total compensation of $3,458,267 for fiscal year 2025.
| Salary | $629,167 |
|---|---|
| Bonus | $0 |
| Stock awards | $2,367,000 |
| Option awards | $0 |
| Non-equity incentive plan | $457,600 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $4,500 |
| Total | $3,458,267 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Maze Therapeutics, Inc. filed April 28, 2026, accession 0001140361-26-017463.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Misbah Tahir | Chief Financial Officer | $3,964,050 |
| Jason Coloma this page | Chief Executive Officer | $3,458,267 |
| Harold Bernstein | President, Research and Development and Chief Medical Officer | $1,821,383 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Maze Therapeutics, Inc. compensation brief.
Jason Coloma's compensation sits inside Maze Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.